Skip to main content
. 2023 Nov 30;14(11):786. doi: 10.1038/s41419-023-06302-0

Fig. 7. Nanosac-encapsulated siRNA (siβ-catenin) enhances the anti-tumor efficacy of sorafenib.

Fig. 7

A Fluorescence microscopy of C11-BODIPY using Huh7 cells transfected with siDDX5 and incubated with Nanosac-encapsulated siCtrl or siβ-catenin for 24 h, followed by the addition of SOR (10 μM) for 24 h. B Quantification by ImageJ software of ratio of oxidized (510 nm)/non-oxidized (590 nm) C11-BODIPY. Data are shown as mean ± SEM from 500 cells. *p < 0.05, **p < 0.01 by unpaired t-test. C Diagram illustrates treatment groups and timetable of intra-tumoral injection of Nanosac-encapsulated siRNAs. D Images of Huh7 xenograft tumors excised on day 19, following three intra-tumoral injections/week of indicated Nanosac-encapsulated siRNAs (3.0 µg siRNA/injection), and daily administration of SOR (80 mg/kg). E Tumor weight from indicated treatment groups, from eight tumors. *p < 0.05 by unpaired t-test. F RT-PCR quantification of β-catenin mRNA using total RNA isolated from Huh7 tumors treated with indicated Nanosac-encapsulated siRNAs +SOR. Data are expressed as mean ± SEM from eight tumors.*<p.05 by unpaired t-test. Quantification of; G MDA (nmole/mg tissue) and H 4-HNE (µg/mg tissue) using Huh7 xenograft tumors treated as indicated. Data are expressed as mean ± SEM from eight tumors. ***p < 0.001 by unpaired t-test.